Sign in Subscribe

targeted-therapy

A collection of 104 issues

Selenium nanoparticles selectively target KRAS G13D mutation

Skip to content The CRC Digest ◇ RESEARCH Selenium nanoparticles selectively target KRAS G13D mutation Researchers developed selenium nanoparticles that specifically inhibit tumors driven by the KRAS G13D mutation—a variant that currently has no approved targeted therapies—by upregulating the tumor suppressor GPX2 and blocking metastasis pathways. (Advanced Science) This

RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC

Skip to content The CRC Digest ▸ TREATMENT RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC A case report describes a patient with RAF1 S257L-mutated, anti-EGFR-refractory metastatic CRC who achieved radiographic response and performance status improvement with avutometinib (RAF/MEK clamp inhibitor) plus cetuximab. (Oncologist) This content

Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC

Skip to content The CRC Digest ▸ TREATMENT Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC Telisotuzumab adizutecan, which delivers a topoisomerase inhibitor to c-MET-expressing tumor cells, achieved an objective response rate of 15.6% in 122 heavily pretreated metastatic colorectal cancer patients in a phase

Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC In the phase Ib CodeBreaK 101 trial, the triple combination of sotorasib (a KRAS G12C inhibitor), panitumumab, and FOLFIRI chemotherapy was tested in previously treated patients with KRAS G12C-mutated metastatic

KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed

Skip to content The CRC Digest KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed A review article discusses how KRAS G12C mutations account for 3% to 4% of metastatic colorectal cancer cases and explains why combined KRAS G12C and EGFR inhibition may be more effective than monotherapy. (Journal of

FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC A multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist) This content is informational only and does not

BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC A randomized study compared encorafenib plus cetuximab and FOLFIRI against FOLFIRI with or without bevacizumab in patients with BRAF V600E-mutant colorectal cancer. (Annals of Oncology) This content is informational only

Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib

Skip to content The CRC Digest ♥ LIVING WITH CRC Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib Researchers developed a weighted toxicity score to help patients and clinicians compare side effects between two later-line treatment options, supporting more informed treatment decisions in metastatic colorectal cancer. (Clinical Colorectal Cancer)

New gene circuit platform targets multiple KRAS mutations in preclinical models

Skip to content The CRC Digest ◇ RESEARCH New gene circuit platform targets multiple KRAS mutations in preclinical models Researchers developed a platform that enables in vivo self-assembly of small extracellular vesicles encapsulating KRAS-specific siRNAs for broad targeting of KRAS mutants, showing activity in orthotopic models of KRAS G12D-, G12V-, and

Trifluridine/tipiracil outcomes examined in patients 75 and older

Skip to content The CRC Digest ▸ TREATMENT Trifluridine/tipiracil outcomes examined in patients 75 and older A single-center retrospective study compared relative dose intensity, toxicity, and survival between trifluridine/tipiracil (FTD/TPI) monotherapy and FTD/TPI plus bevacizumab in older patients with metastatic colorectal cancer, examining the relationship between dose